Alogabat

Alogabat
Clinical data
Other namesGABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773
Routes of
administration		Oral[1]
Drug classα5 subunit-containing GABAA receptor positive allosteric modulator
Identifiers
  • 6-[[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H23N5O4
Molar mass409.446 g·mol−1
3D model (JSmol)
  • CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C
  • InChI=1S/C21H23N5O4/c1-13-3-4-15(11-22-13)20-17(14(2)30-26-20)12-29-19-6-5-18(24-25-19)21(27)23-16-7-9-28-10-8-16/h3-6,11,16H,7-10,12H2,1-2H3,(H,23,27)
  • Key:ACZCJTHHWMBFKC-UHFFFAOYSA-N

Alogabat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.[1][2][3][4] It is taken by mouth.[1]

As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome.[1][2] It is under development by Roche.[1][2]

  1. ^ a b c d e "Alogabat - Genentech". AdisInsight. 28 June 2024. Retrieved 29 October 2024.
  2. ^ a b c "Delving into the Latest Updates on RG-7816 with Synapse". Synapse. 19 September 2024. Retrieved 29 October 2024.
  3. ^ Maramai S, Benchekroun M, Ward SE, Atack JR (April 2020). "Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update". Journal of Medicinal Chemistry. 63 (7): 3425–3446. doi:10.1021/acs.jmedchem.9b01312. PMID 31738537.
  4. ^ Stevens EB, Stephens GJ (2024). "Ion Channels as Targets in Drug Discovery: Outlook and Perspectives". Ion Channels as Targets in Drug Discovery. Cham: Springer International Publishing. p. 1–34. doi:10.1007/978-3-031-52197-3_1. ISBN 978-3-031-52196-6.